CBAY News and Press, CymaBay Therapeutics Inc. From 11/17/21

CymaBay Therapeutics (NASDAQ:CBAY) is trading flat in the post-market after the company announced the start of an underwritten public offering of common stock and pre-funded warrants. A 30-day option allowing underwriters to purchase an additional 15% of the shares of the common stock is also...

NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today a...

CymaBay Therapeutics (NASDAQ:CBAY) announced long-term data from an open-label trial of seladelpar, the company’s experimental therapy for primary biliary cholangitis (PBC), indicating its efficacy following the treatment of one and two years. The results were shared in an oral pr...

Study results presented at The Liver Meeting® 2021 demonstrated continued reductions in biomarkers of cholestasis and hepatocellular injury over two years Seladelpar generally appeared safe with low rates of discontinuation and no liver-related serious adverse events over...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q3 2021 Earnings Call Transcript...

NEWARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a Key Opinion Leader (KOL) web...

CymaBay Therapeutics (NASDAQ:CBAY): Q3 GAAP EPS of -$0.33 misses by $0.08. Press Release For further details see: CymaBay Therapeutics EPS misses by $0.08

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in patients with PBC to be featured at The Liver Meeting ® November 12-15, 202...

CymaBay Therapeutics (NASDAQ:CBAY) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$0.27 (-58.8% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 3 dow...

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...